InCarda Therapeutics is focused on transforming cardiovascular disease treatment through pulmonary delivery of established drugs. The company is product-focused with significant capabilities and led by a team with extensive experience in drug development. The lead product under development is an inhaled therapy intended to treat paroxysmal atrial fibrillation (PAF). InCarda is also working on additional research concepts that leverage the same platform technology to target the heart for acute cardiac conditions. Our approach is designed to reduce the risk normally associated with drug development. Our model is based on the following three tenets: known diseases, known drugs, new delivery.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/28/15 | $5,000,000 | Series A |
Morningside Technology Advisory | undisclosed |
| 10/23/20 | $30,000,000 | Series C |
Deerfield Management Company, L.P. HealthCap Innoviva  | undisclosed |
